AMICUS THERAPEUTICS, INC. (FOLD) Earnings History

AMICUS THERAPEUTICS, INC. - Q3 FY2025 Earnings

Filed at: Nov 4, 2025, 6:39 AM EST|Read from source

EXECUTIVE SUMMARY

Amicus Therapeutics reported a strong third quarter of 2025, achieving revenue growth and reaching GAAP profitability for the first time. The company saw increased patient reach driven by its key products, Galafold and Pombiliti + Opfolda.

POSITIVE HIGHLIGHTS

  • •

    Total revenues increased 19% to $169.1 million, with 17% growth at constant exchange rates (CER).

    positive
  • •

    Achieved GAAP net income of $17.3 million, a significant improvement from a net loss of $6.7 million in the prior year.

    positive
  • •

    Cash, cash equivalents, and marketable securities increased to $263.8 million.

    positive
  • •

    Pombiliti + Opfolda net product sales grew 45% (42% at CER) to $30.7 million.

    positive

CONCERNS & RISKS

  • •

    Total GAAP operating expenses increased by 8% to $115.3 million, while non-GAAP operating expenses increased by 15% to $95.4 million.

    attention
  • •

    Research and development expenses decreased by 11% year-over-year for the quarter, potentially indicating a shift in investment.

    attention
  • •

    Inventories increased significantly from $118.8 million at the end of 2024 to $177.9 million at the end of Q3 2025.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$169.06M
+19.5%
Prior year: $141.52M
Annual (YTD)
$449.00M
N/A
Prior year: $378.59M
Net Income
Quarterly
$17.31M
-357.5%
Prior year: $-6.73M
Annual (YTD)
$-28.80M
N/A
Prior year: $-70.84M
EPS (Diluted)
Quarterly
$0.06
-400.0%
Prior year: $-0.02
Annual (YTD)
$-0.09
N/A
Prior year: $-0.23
Operating Income
Quarterly
$34.27M
+58.2%
Prior year: $21.66M
Annual (YTD)
$16.84M
N/A
Prior year: $8.90M
EPS (Basic)
Quarterly
$0.06
-400.0%
Prior year: $-0.02
Annual (YTD)
$-0.09
N/A
Prior year: $-0.23

MARGIN ANALYSIS

Gross Margin
Current Quarter
88.5%
Prior Year
90.6%
YoY Change
-210 bps
Operating Margin
Current Quarter
20.3%
Prior Year
15.3%
YoY Change
+497 bps
Net Margin
Current Quarter
10.2%
Prior Year
-4.8%
YoY Change
+1499 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

MANAGEMENT GUIDANCE

FY 2025

Total Revenue Growth
$15.0M—$22.0M
Mid-point: $18.5M
"Reiterated guidance"
Galafold Revenue Growth
$10.0M—$15.0M
Mid-point: $12.5M
"Reiterated guidance"
Pombiliti + Opfolda Revenue Growth
$50.0M—$65.0M
Mid-point: $57.5M
"Reiterated guidance"
Gross Margin
85.0%
"Mid 80%"
Non-GAAP Operating Expenses
380,000,000—400,000,000
Mid-point: 390,000,000
"Reiterated guidance"

H2 2025

GAAP Net Income
"Positive during H2 2025"

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

SPECIAL ITEMS & ADJUSTMENTS

Q3 2024
Restructuring charges
Impacted prior year results.
+$3.143M
Nine Months 2025
Loss on impairment of assets
Impacted year-to-date results.
+$1.702M
Nine Months 2024
Restructuring charges
Impacted prior year-to-date results.
+$9.188M
Total Impact
+$14.033M

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Achieved revenue growth of 17 percent and reached the milestone of GAAP profitability.

— AMICUS THERAPEUTICS, INC., Q3 FY2025 2025 Earnings Call

Served more patients than ever before, driven by new Galafold starts and growing adoption for Pombiliti + Opfolda.

— AMICUS THERAPEUTICS, INC., Q3 FY2025 2025 Earnings Call

Enrollment in the Phase 3 study of DMX-200 remains on track for completion by year-end.

— AMICUS THERAPEUTICS, INC., Q3 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Galafold Revenue Growth Cer
12
percent
Pombiliti Opfolda Revenue Growth Cer
42
percent

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.